

1 **Saliva as a testing sample for SARS-CoV-2**

2 **detection by RT-PCR in low prevalence**

3 **community settings**

4 Didzis Gavars¹, Mikus Gavars¹, Dmitry Perminov^{1,4}, Janis Stasulans¹,

5 Justine Stana¹, Zane Metla¹, Jana Pavare³, Eriks Tauckels¹, Egils

6 Gulbis¹, Uga Dumpis^{2,4}

7 1 - E.Gulbja Laboratory, Riga, Latvia

8 2 - Pauls Stradins Clinical University Hospital, Riga Latvia

9 3 - Children's Clinical University Hospital, Riga Stradins University,
10 Riga, Latvia

11 4 - University of Latvia, Riga, Latvia

12 **Corresponding author:**

13 Dr. Didzis Gavars, E.Gulbja Laboratory

14 Brivibas str.366, Riga, Latvia, LV-1006

15 email: didzis@egl.lv;

16 telephone: +37129259742; fax: +37167543867

17 **Abstract**

18 **Objectives**

19 The number of COVID-19 cases is increasing globally and there is an
20 urgency for a simple non-invasive method for the detection of SARS-
21 CoV-2. Our study aimed to demonstrate that saliva can be used as a
22 specimen for SARS-CoV-2 detection notably for the screening of
23 extensive population groups via pooling.

24 **Methods**

25 To demonstrate that saliva is an appropriate specimen for SARS-CoV-
26 2 detection a field study including 3,660 participants was performed
27 between September 29 and October 1, 2020. We collected paired
28 nasopharyngeal/oropharyngeal swabs (NPS) and saliva specimens and
29 processed them within 24 hours of collection. We performed 36 serial
30 measurements of 8 SARS-CoV-2 positive saliva samples to confirm
31 the stability of the specimen and completed 37 pools of saliva samples
32 by adding one positive specimen per pool.

33 **Results**

34 Saliva specimens were stable for testing for up to 24 hours. Overall,
35 44 salival samples (1.2%) tested positive for SARS-CoV-2 during the
36 field study. The results of saliva samples were consistent with those
37 obtained from NPS from the same patient with 90% sensitivity (95%
38 CI 68.3%-98.7%) and 100% specificity during the first two weeks after
39 the onset of symptoms. Using pooling strategy 796 RT-PCR tests were
40 performed. All pools showed 100% positivity in different pooling
41 proportions.

42 **Conclusions**

43 Our findings demonstrate that saliva is an appropriate specimen for
44 pooling and SARS-CoV-2 screening with accurate diagnostic
45 performance. Patient-performed simple specimen collection allows
46 testing an extensive number of people rapidly, obtaining results of the
47 spread of SARS-CoV-2 and allowing authorities to take timely
48 measures.

49

50 **Introduction**

51 Since the beginning of 2020 massive resources have been dedicated to
52 control and mitigate the COVID-19 pandemic. Testing capacity and
53 accessibility are crucial in monitoring COVID-19 outbreaks and
54 allowing for the adjustment of measures put into place to reduce
55 community transmission (1).

56 Viral nucleic acid detection using the real-time polymerase chain
57 reaction (RT-PCR) assay remains the gold standard for the detection
58 of SARS-CoV-2 and to diagnose COVID-19 (2). Due to the increased
59 demand for sampling and testing materials globally considerable
60 constraints remain to conduct widespread screening for SARS-CoV-2.
61 It is especially challenging for counties with low prevalence levels as
62 global suppliers allocate materials and decide delivery schedules based
63 on the prevalence of the virus.

64 Shortages of supplies and medical staff, logistical hurdles, as well the
65 unpleasantness associated with obtaining a RT-PCR specimen making
66 it difficult to practice the procedure on children and causing irritation
67 for those who need to undergo repeated tests, all these factors have
68 naturally accelerated research into alternative specimens and sampling
69 methods for COVID-19 testing (3,4).

70 On September 21, 2020, Latvia had a 14-day cumulative number of
71 COVID-19 cases of 5.1 per 100,000 people. By October 10 that
72 number had risen to 66. During this period, laboratories experienced a
73 significant overload (5). Rapid and efficient solutions to increase
74 testing capacity were needed.

75 The objective of this study was to confirm that saliva is a suitable
76 specimen comparable to a nasopharyngeal/oropharyngeal swab for
77 SARS-CoV-2 detection in specific populations. We also evaluated the
78 pooling approach to employ it in field conditions for extensive
79 screening of high-risk groups.

80

81 **Methods**

82 *Patient sample collection*

83 A single-center study was performed including all consented patients
84 attending the laboratory for SARS-CoV-2 testing between May 12 and
85 October 19, 2020. For the collection of the saliva samples, self-
86 collection kits were distributed consisting of a specimen vial,
87 registration form, alcohol pads for disinfection, and two safety plastic
88 bags. Patients were requested to collect their saliva in an isolated
89 location (keeping at least five meters distance from other persons or
90 objects), preferably outdoors, at home, or in their car. The saliva was
91 collected in a container without any additive and delivered to the
92 laboratory within 24 hours. Paired nasopharyngeal/oropharyngeal
93 swabs (NPS) for RT-PCR were collected using the standard method
94 used in our laboratory (6).

95 *Sample preparation and analysis using RT-PCR*

96 Immediately upon arrival at the laboratory, the samples were
97 pretreated by adding 1 ml of phosphate-buffered saline (PBS). The
98 extraction of RNA and RT-PCR testing was identical for both swab
99 and pre-treated saliva samples. Viral RNA was extracted with standard
100 commercial extraction methods (QIAGEN, Germany and LifeRiver,
101 China) used in our laboratory. RT-PCR was performed using our
102 laboratory-developed and validated test method which detects S and N
103 genes of the SARS-CoV-2 virus. Our validated and verified limit of
104 detection (LOD) was 1 cp/rxn.

105

106 **Results**

107 *Stability of saliva specimens*

108 To confirm the stability of saliva samples, we performed 36 serial tests
109 on 8 primary SARS-CoV-2 positive saliva samples collected from
110 patients 48 hours after their NPS tested positive. The data are
111 summarized in Tables 1-3. Testing was randomized by different time
112 intervals, the time of day, and the shifts of technicians. It includes
113 repeated testing of two samples after 22h (Table 2) and serial repeats
114 of one sample (Table 3) with Ct value reporting.

115 All results confirmed a positive result after 22-25h of the first test
116 being conducted. Samples were stored refrigerated at 2-6°C between
117 tests.

118 *Comparison of saliva and nasopharyngeal/oropharyngeal samples*

119 Between May 13 and September 21, 2020, 431 tests on saliva samples
120 were performed, and the results were compared with paired NPS RT-
121 PCR test results. Using NPS RT-PCR as the reference, there were

122 104 PCR positive samples and 327 negative patients, including
123 125 pediatric (age 5-17 years (average 11.3 years)) samples. The
124 observed RT-PCR positive results were divided into groups according
125 to the number of days after the onset of symptoms: 0-14 days (22
126 patients); 15-30 days (52 patients); 31-70 days (20 patients) and
127 10 asymptomatic patients. The results of the comparison of the
128 mentioned subgroups are presented in Table 4.

129 Sensitivity and specificity for the respective groups were: for 0-14
130 days 90% (95%CI 68.3%-98.7%) and 100% (95%CI 22.4%-100%);
131 for 15-30 days 64.7% (95% CI 46.5%-80.3%) and 83.3% (95%CI
132 58.9%-96.4%); for 31-70 days 71.4% (95%CI 29.0%-96.3%) and
133 84.6% (95%CI 54.6%-98.1%); for asymptomatic 71.4% (95%CI
134 29.0%-96.3%) and 66.7% (95%CI 0.8%-90.6%). The mean Ct values
135 for the groups were 33.9 for NPS and 33.8 for saliva (0-14 days), 34.8
136 for NPS and 34 for saliva (15-30 days), and 36.5 for NPS and 39 for
137 saliva in the asymptomatic patient group.

138 ***Pooling of saliva***

139 To evaluate the testing of pooled saliva samples, 37 pools were
140 constituted. There were 15 pools of 5 samples (4 negatives + 1
141 positive), 13 pools of 10 samples (9 negatives + 1 positive), and
142 9 pools of 20 samples (19 negatives + 1 positive). The RT-PCR testing
143 for each pool was repeated twice. The total number of measurements
144 was 74. All results were 100% positive.

145 When using pooling, the number of tests needed per sample was
146 calculated as follows: the total number of tests needed to test all
147 samples is divided by the total number of samples. For example, if

148 500 samples are being tested in pools of 10, it means 50 tests are
149 initially needed. With a positivity rate of 1%, a maximum of five pools
150 will contain a positive specimen (if each positive sample is in a
151 different pool). The 50 samples from these five pools will have to be
152 retested individually (each of the five positive pools contains 10
153 samples). Therefore, a total of 100 tests are needed to evaluate all
154 500 samples and the number of tests per sample is $100/500 = 0.2$.

155 The positivity rate in Latvia on September 23, 2020, was 0.5%.

156 The approximate positivity rate at which the pooling of 5 samples
157 becomes more efficient than the pooling of 10 samples is 3% (2-4%
158 depending on test price, laboratory load, tests per sample).

159 *Field study*

160 To evaluate the convenience of saliva pool testing by RT-PCR in field
161 conditions, the town of Kuldīga (total population 10,352) with an
162 ongoing outbreak of COVID-19 in a textile factory was selected. In
163 collaboration with local authorities, 4,100 saliva self-sampling kits
164 were distributed to inhabitants at a specially established distribution
165 point. There were four persons dedicated to the distribution of the kits
166 and four drivers to deliver the samples by car to the testing laboratory
167 in Riga (150 km one way). During the study period, 3,660 saliva
168 samples were collected (response rate 91.5%), delivered to the
169 laboratory, and tested in pools of 10 samples. There were a total of
170 366 pools. In the first round of testing 43 pools were found to be
171 positive and samples from these pools were re-tested individually. The
172 saliva samples from 44 patients were confirmed as positive by RT-
173 PCR. Mean Ct values of pooled samples were 13% higher than

174 individually tested Ct (31.6 versus 27.6). The positivity rate of the
175 tested population was 1.2%. In total 796 RT-PCR tests were
176 performed. At the time of the sample collection, 68.2% (30/44) of
177 patients did not report any symptoms on the questionnaire form.

178 Nasopharyngeal swab tests and saliva tests were compared with the
179 number of new COVID-19 cases. The findings illustrate that the
180 second peak in new cases occurred 6-7 days after the initial peak. Such
181 findings correspond with the mean incubation period of the SARS-
182 CoV-2. The results reflect a decrease in new cases in the following
183 observation period (Figure 1).

184

185 **Discussion**

186 The findings of our study can be summarized as follows: (a) for the
187 detection of SARS-CoV-2, saliva is a stable specimen with acceptable
188 specificity and sensitivity at the early stages of infection; (b) saliva
189 specimen is appropriate for pooling, with accurate diagnostic
190 performance.

191 Saliva has been identified as a reliable testing specimen for SARS-
192 CoV-2 using the RT-PCR approach in several recent studies (7–9). In
193 the updated European Centre for Disease Prevention and Control
194 (ECDC) recommendations, saliva is also mentioned as a convenient
195 specimen for SARS-CoV-2 testing (10,11). The FDA has approved
196 methods for SARS-CoV-2 testing using saliva in several laboratories
197 (12,13). Nevertheless, saliva has been included in IFCC COVID-19
198 Guidelines on Molecular, Serological, and
199 Biochemical/Haematological Testing as a promising sample type (14).

200 The high expression of ACE2 receptors in salivary gland cells is the
201 main factor for virus affinity that could lead to active replication and
202 transmission by saliva droplets expelled into the air during coughing
203 or sneezing (15,16).

204 It is essential to establish standardized sample collection procedures,
205 safe logistics, and reliable testing methods that meet performance
206 requirements. Our stability testing confirmed that saliva samples
207 stayed equally positive up to 24h.

208 In the analytical context, saliva can have the same or even better
209 performance than NPS (17). It has been previously confirmed to be
210 highly sensitive and specific at the early stage of infection 0-14 days
211 after onset of symptoms and in asymptomatic cases (17,18). Therefore,
212 it is essential to take into consideration the relationship between the
213 dynamics of viral load, Ct values, and the number of days after the
214 onset of symptoms. As described in prior publications, the Ct value is
215 important in determining the infectiousness of a patient sample. Ct
216 values above 34 do not emit infectious virus particles, and values
217 between 27-34 show low viability of the viral load. Samples with a Ct
218 value of 13-17 show positive virus viability (19). Ct values may vary
219 depending on the different assays by up to 5 cycles for the same sample
220 (20). Variation also appears due to the quality of the specimen obtained
221 and the different treatment methods used to prepare samples for testing
222 (21). As expected, we got some variation between the NPS and saliva
223 sample types. In our pilot testing using 44 positive saliva samples we
224 found slightly higher (13%) Ct values in pools, compared to individual
225 tests. Similar findings have been published by other researchers (22).
226 This observed slight difference still allows for the safe use of saliva

227 pooling for surveillance purposes with sufficient diagnostic accuracy.
228 Nevertheless, pooling strategies are described in the latest update of
229 COVID-19 testing strategies and objectives published by the ECDC
230 (11). There is evidence of benefits from pooling in low prevalence
231 countries with a low proportion of positive samples – up to 5%. Recent
232 publications indicate that for populations with a prevalence of less than
233 1% the testing of saliva pools of 10 or 20 samples is more beneficial,
234 and our independent calculations also bear this out. Comparing the
235 correlation between different pool sizes (usefulness and efficiency)
236 with test positivity rate, we concluded that a pool size of 10 is more
237 efficient than a pool size of 5. The calculations are based on test price,
238 reimbursement conditions, and the number of tests per sample (when
239 using a pooling strategy) (23,24).

240 The pooling strategy for self-collected saliva samples is the optimal
241 solution that saves resources and reduces the testing time (25). In our
242 real-life field test on a “perifocal” population, we successfully tested
243 nearly a third of the citizens of the town of Kuldiga in three days. This
244 allowed for fast identification of asymptomatic SARS-CoV-2 cases
245 and those with mild symptoms to enable timely contact tracing and
246 outbreak containment. The use of nasopharyngeal swabs in such a
247 situation would have required more staff and time with possible patient
248 compliance issues.

249 Additionally, improvements may reasonably be expected in terms of
250 organizing the distribution of self-sampling kits to patients as well as
251 the logistics of returning the kits to the laboratory that would further
252 increase the usefulness of screening using a pooled testing strategy.

253 There were some limitations in our study: the size of the cohort of
254 participants was limited, the selected laboratory-developed RT-PCR
255 method for evaluation was used, also a lack of multicenter observation.
256 Future studies extending the cohort are needed to confirm current
257 findings and provide the implications in clinical practice.

258

259 **Conclusions**

260 Our findings confirm the stability of SARS-CoV-2 RNA in saliva,
261 showing acceptable performance in terms of specificity and sensitivity
262 at the early stages of infection, and the advantages of testing using a
263 pooling strategy in a low prevalence population. Ct values and
264 detected/missing gene information are favorable for the interpretation
265 of the results from several aspects, e.g. epidemiological investigation,
266 determination if the patient is infectious at the current stage, etc. Self-
267 sampling makes the procedure faster, safer, and requires fewer
268 resources. The targeted distribution of test kits among a population
269 with a known outbreak significantly increased the positivity rate.
270 Saliva pool testing on a large scale provides an additional tool to take
271 timely measures and contain outbreaks.

272

273 **Ethical aspects**

274 The study was approved by the Ethics Committee of the Pauls Stradins
275 Clinical University Hospital (record No 300720-18L).

276

277 **Acknowledgments**

278 We gratefully acknowledge all participants for their commitment to
279 participate and their time. Special thanks to all trial team members in
280 the E.Gulbja Laboratory for their dedication and work which made this
281 study possible and Dr. A.Gramatniece for editorial help.

282

283 **Author contributions**

284 Gavars D - the conception and design of the study, Gavars M,
285 Perminovs D, and Metla Z – validation of the method and
286 interpretation of the data, Stasulans J, Stana J - patient recruitment and
287 data collection, drafting of the article, Tauckels E - data analysis,
288 Gulbis E, and Dumpis U – revising the article critically, final approval
289 of the version to be submitted.

290

291 **Transparency declaration**

292 All authors declare that there are no conflicts of interest.

293

294 **Funding institution:**

295 Ministry of Education and Science, Republic of Latvia. Funding
296 number: VPP-COVID-2020/1-0008.

297 Additional funding was provided by E.Gulbja laboratory.

298

299 **References:**

300 1. Rapid Risk Assessment: Coronavirus disease 2019 (COVID-19)
301 in the EU/EEA and the UK– ninth update [Internet]. European

- 302 Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
303 16]. Available from: [https://www.ecdc.europa.eu/en/publications-](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-ninth-update)
304 [data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-ninth-update)
305 [pandemic-ninth-update](https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-coronavirus-disease-2019-covid-19-pandemic-ninth-update)
- 306 2. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in
307 suspected human cases [Internet]. [cited 2020 Nov 16]. Available
308 from: [https://www.who.int/publications-detail-redirect/10665-](https://www.who.int/publications-detail-redirect/10665-331501)
309 [331501](https://www.who.int/publications-detail-redirect/10665-331501)
- 310 3. COVID-19: Overcoming supply shortages for diagnostic testing |
311 McKinsey [Internet]. [cited 2020 Nov 16]. Available from:
312 [https://www.mckinsey.com/industries/pharmaceuticals-and-](https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-overcoming-supply-shortages-for-diagnostic-testing#)
313 [medical-products/our-insights/covid-19-overcoming-supply-](https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-overcoming-supply-shortages-for-diagnostic-testing#)
314 [shortages-for-diagnostic-testing#](https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-overcoming-supply-shortages-for-diagnostic-testing#)
- 315 4. Jeong HW, Kim S-M, Kim H-S, Kim Y-I, Kim JH, Cho JY, et al.
316 Viable SARS-CoV-2 in various specimens from COVID-19
317 patients. *Clin Microbiol Infect*. 2020 Nov;26(11):1520–4.
- 318 5. COVID-19 situation update for the EU/EEA and the UK, as of 16
319 November 2020 [Internet]. European Centre for Disease
320 Prevention and Control. [cited 2020 Nov 16]. Available from:
321 <https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea>
- 322 6. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal
323 Swab Specimen. *N Engl J Med*. 2020 May 28;382(22):e76.
- 324 7. Fakheran O, Dehghannejad M, Khademi A. Saliva as a diagnostic
325 specimen for detection of SARS-CoV-2 in suspected patients: a
326 scoping review. *Infect Dis Poverty*. 2020 Jul 22;9(1):100.
- 327 8. Hamid H, Khurshid Z, Adanir N, Zafar MS, Zohaib S. COVID-19
328 Pandemic and Role of Human Saliva as a Testing Biofluid in
329 Point-of-Care Technology. *Eur J Dent* [Internet]. 2020 Jun 3 [cited

- 330 2020 Nov 16]; Available from: [http://www.thieme-](http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1713020)
331 [connect.de/DOI/DOI?10.1055/s-0040-1713020](http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1713020)
- 332 9. Czumbel LM, Kiss S, Farkas N, Mandel I, Hegyi A, Nagy Á, et
333 al. Saliva as a Candidate for COVID-19 Diagnostic Testing: A
334 Meta-Analysis. *Front Med.* 2020 Aug 4;7:465–465.
- 335 10. Objectives for COVID-19 testing in school settings - first update,
336 21 August 2020. Tech Rep. 2020;4.
- 337 11. COVID-19 testing strategies and objectives [Internet]. European
338 Centre for Disease Prevention and Control. 2020 [cited 2020 Nov
339 16]. Available from: [https://www.ecdc.europa.eu/en/publications-](https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strategies-and-objectives)
340 [data/covid-19-testing-strategies-and-objectives](https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strategies-and-objectives)
- 341 12. Commissioner O of the. Coronavirus (COVID-19) Update: FDA
342 Authorizes First Diagnostic Test Using At-Home Collection of
343 Saliva Specimens [Internet]. FDA. FDA; 2020 [cited 2020 Nov
344 16]. Available from: [https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva)
345 [announcements/coronavirus-covid-19-update-fda-authorizes-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva)
346 [first-diagnostic-test-using-home-collection-saliva](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-diagnostic-test-using-home-collection-saliva)
- 347 13. Rutgers Launches Genetic Testing Service for New Coronavirus |
348 Rutgers University [Internet]. [cited 2020 Nov 16]. Available
349 from: [https://www.rutgers.edu/news/rutgers-launches-genetic-](https://www.rutgers.edu/news/rutgers-launches-genetic-testing-service-new-coronavirus)
350 [testing-service-new-coronavirus](https://www.rutgers.edu/news/rutgers-launches-genetic-testing-service-new-coronavirus)
- 351 14. Bohn M, Mancini N, Loh P, Wang C-B, Grimm M, Gramegna
352 M, et al. IFCC interim guidelines on molecular testing of SARS-
353 CoV-2 infection. *Clin Chem Lab Med.* 2020 Oct 7;
- 354 15. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, et al. Epithelial
355 Cells Lining Salivary Gland Ducts Are Early Target Cells of
356 Severe Acute Respiratory Syndrome Coronavirus Infection in the

- 357 Upper Respiratory Tracts of Rhesus Macaques. *J Virol*. 2011 Apr
358 15;85(8):4025–30.
- 359 16. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential
360 Reservoirs for COVID-19 Asymptomatic Infection. *J Dent Res*.
361 2020;99(8):989.
- 362 17. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M,
363 Tokuyama M, Vijayakumar P, et al. Saliva or Nasopharyngeal
364 Swab Specimens for Detection of SARS-CoV-2. *N Engl J Med*.
365 2020;4.
- 366 18. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al.
367 Molecular and serological investigation of 2019-nCoV infected
368 patients: implication of multiple shedding routes. *Emerg Microbes*
369 *Infect*. 2020 Feb 17;9(1):386–9.
- 370 19. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C,
371 Colson P, et al. Viral RNA load as determined by cell culture as a
372 management tool for discharge of SARS-CoV-2 patients from
373 infectious disease wards. *Eur J Clin Microbiol Infect Dis*. 2020
374 Apr 27;1–3.
- 375 20. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R,
376 Shrestha L, et al. Comparative Performance of SARS-CoV-2
377 Detection Assays Using Seven Different Primer-Probe Sets and
378 One Assay Kit. *J Clin Microbiol*. 2020 26;58(6).
- 379 21. Rodino KG, Espy MJ, Buckwalter SP, Walchak RC, Germer JJ,
380 Fernholz E, et al. Evaluation of Saline, Phosphate-Buffered
381 Saline, and Minimum Essential Medium as Potential Alternatives
382 to Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ,
383 editor. *J Clin Microbiol*. 2020 May 26;58(6):e00590-20.

- 384 22. Lohse S, Pfuhl T, Berkó-Göttel B, Rissland J, Geißler T, Gärtner
385 B, et al. Pooling of samples for testing for SARS-CoV-2 in
386 asymptomatic people. *Lancet Infect Dis.* 2020 Nov
387 1;20(11):1231–2.
- 388 23. Regen F, Eren N, Heuser I, Hellmann-Regen J. A simple approach
389 to optimum pool size for pooled SARS-CoV-2 testing. *Int J Infect*
390 *Dis.* 2020 Nov 1;100:324–6.
- 391 24. Mutesa L, Ndishimye P, Butera Y, Souopgui J, Uwineza A,
392 Rutayisire R, et al. A pooled testing strategy for identifying
393 SARS-CoV-2 at low prevalence. *Nature.* 2020 Oct 21;1–8.
- 394 25. Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-
395 19 surveillance programme. *Lancet Respir Med.*
396 2020;8(11):1078–80.
- 397




Table 1 Run No. 1 on saliva stability measurements of 5 samples collected 2-4h before the first testing

	0	after 8h	after 24h	after 25h
	<i>1st 14:00</i>	<i>2nd 22:00</i>	<i>3rd 14:00</i>	<i>4th 15:00</i>
1	Positive	Positive	Positive	Positive
2	Positive	Positive	Positive	Positive
3	Positive	W- Positive	Positive	W- Positive
4	Positive	Positive	Positive	No sample left
5	Positive	W- Positive	Positive	W- Positive

Abbreviations: W-Positive - weak positive result, h - hours

Table 2 Run No. 2 on saliva stability serial measurements of two samples collected 2-4h before first testing

	0	after 12h	after 22h	after 22h rep.
	<i>1st 12:00</i>	<i>2nd 00:00</i>	<i>3rd 10:00</i>	<i>4th 10:00</i>
6	W- Positive	Positive	Positive	Positive
Ct	35	36	37	37
7	Positive	Positive	Positive	Positive
Ct	32	33	30	31

Abbreviations: W-Positive - weak positive result, rep. - repeats, h – hours

Table 3 Run No. 3 on saliva repeatability measurements of one sample collected 2 - 4h before the first testing with indicated Ct values

	0	after 3h	after 12h	after 24h
	<i>1st 11:00</i>	<i>2nd 14:00</i>	<i>3rd 02:00</i>	<i>4th 11:00</i>
8	Positive	Positive	Positive	Positive
Ct	34	30	33	35
8 rep.	Positive	Positive	Positive	Positive
Ct	34	27	31	35

Abbreviations: rep. - repeats, h – hours

Table 4 Saliva samples compared to the results of nasopharyngeal/ oropharyngeal swabs

Days after the start of symptoms		NPS							
		0-14		15-30		31-70		Asymptomatic	
RT-PCR		Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative
Saliva	Positive	18	0	22	3	5	2	5	1
	Negative	2	2	12	15	2	11	2	2
Sensitivity %		90		64.7		71.4		71.4	
Specificity %		100		83.3		84.6		66.7	

Abbreviations: NPS - nasopharyngeal/ oropharyngeal swabs, RT-PCR – real-time polymerase chain reaction